Use access key #2 to skip to page content.
$11.49 -0.24 (-2.05%)
8/21/2008 4:00 PM

Seattle Genetics, Inc. (SGEN)

CAPS Rating:
***

A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating SGEN

Add Stock to Watchlist

What the Community Thinks

Total Members

247 Outperforms
21 Underperforms
 

All-Stars

61 Outperforms
8 Underperforms
 

Wall Street

8 Outperforms
0 Underperforms
 

Members bullish on SGEN are also bullish on:

Members bearish on SGEN are also bearish on:

Ticker Tags

Small Cap (1922), Rule Breakers Universe (161), Biotechnology (294)
Suggest a tag

Seattle Genetics, Inc. At A Glance

Current Price: $11.49
Last Trade Time: 8/21/2008 4:00 PM
Open: $11.59
Previous Close: $11.73
Daily Range: $11.41 - $11.95
52-Week Range: $7.20 - $13.44
Volume: 423,740
Market Cap: $934.22M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

SGEN VS S&P 500 (SPY)

SGEN 12 month chart vs. S&P

News & Discussion Boards

Other News Headlines for SGEN

More Headlines...

Top Bull Pitch

Recs

1

Seattle Genetics, Inc. (SGEN)

Avatar Swarlington (< 20) Submitted: 2/26/08 6:01 AM

Seattle Genetics is a solid Biotech company with outstanding potential. The insider buying has been great as they are very near Phase III trials. One year sales growth is 99.70% and Genetics is the future for medicine. Although Baby-Boomers are giving great potential to any drug company, as with all...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

1

Seattle Genetics, Inc. (SGEN)

Avatar georicheck (< 20) Submitted: 8/03/07 11:48 AM

Needs a product to succeed.

Replies: 0 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 47 :   1 2 3 4 5 Next » Jump to page:

Show Pitch Replies

Recs

0

 (SGEN)

Avatar zzlangerhans (95.24) Submitted: 7/24/08 3:20 PM : Underperform Start Price: $11.09 SGEN Score: -3.99

I have to hand it to the boys from Seattle for keeping their share price up despite a deficiency of late stage trials and a fat burn. Other baby bios in a similar position have had their asses handed to them in this market. But now we're nearing a year high after a sharp upswing on no good news that I've been able to identify. I think we'll be headed back down again shortly.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (SGEN)

Avatar CraigMiles (41.74) Submitted: 7/24/08 10:19 AM : Outperform Start Price: $11.20 SGEN Score: 2.21

If they can get something out into the market they will explode! And on that gamble I will say outperform.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (SGEN)

Avatar Jorgedig (67.28) Submitted: 6/04/08 8:07 PM : Outperform Start Price: $8.54 SGEN Score: 42.44

I like the Hodgkins drug.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (SGEN)

Avatar FleaBagger (99.21) Submitted: 5/14/08 11:07 AM : Outperform Start Price: $10.11 SGEN Score: 23.34

Following Zz.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (SGEN)

Avatar TMFHelical (99.26) Submitted: 5/13/08 9:40 PM : Outperform Start Price: $10.10 SGEN Score: 23.12

I always liked what this biotech was doing, but it never seemed right to make the bullish call. Well, what the heck, now looks good. SGEN has some good programs and a solid cash / partnership position to see some to fruition. Another buy and try to ignore for a decade biotech.

Report this Post Replies: 3 | Reply | Permalink

Results 1 - 5 of 47 :   1 2 3 4 5 Next » Jump to page:

Wall Street

Results 1 - 8 of 8  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackRBCCapMkts 94.50 03/19/08 Outperform NS $8.63+33.14%-4.73%+37.87
TrackMichaelBrus 94.06 02/14/08 Outperform 1Y $9.35+22.89%-5.45%+28.34
TrackJPMorgan 91.17 01/28/08 Outperform NS $9.34+23.02%-4.10%+27.12
TrackFortisBank 98.24 09/21/07 Outperform NS $11.79-2.54%-16.31%+13.77
TrackWMBlair < 20 08/21/07 Outperform NS $11.03+4.17%-11.66%+15.83
TrackBofASec 97.33 12/12/06 Outperform NS $6.17+86.22%-9.80%+96.03
TrackNeedham < 20 10/25/06 Outperform NS $4.92+133.54%-7.24%+140.78
TrackNextGen < 20 10/06/06 Outperform NS $4.95+132.12%-5.24%+137.36

Results 1 - 8 of 8  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners